On September 8, 2024 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, reported that it will present the latest clinical data of olverembatinib (HQP1351), the company’s novel drug candidate, in patients with succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST), in a Mini Oral at the 2024 European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress (Press release, Ascentage Pharma, SEP 8, 2024, View Source;ascentage-pharma-to-present-updated-data-of-olverembatinib-in-patients-with-sdh-deficient-gist-during-a-mini-oral-presentation-at-the-2024-esmo-congress-302241379.html [SID1234646410]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As one of the world’s leading and most influential oncology congresses, the ESMO (Free ESMO Whitepaper) Congress showcases the latest results in some of the most cutting-edge cancer research from around the world. This year, the ESMO (Free ESMO Whitepaper) Congress will be held from September 13 to 17 in Barcelona, Spain.
"We are pleased to have this opportunity to showcase olverembatinib’s therapeutic potential for the treatment of SDH-deficient GIST," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "As a third-generation TKI developed in house by Ascentage Pharma, olverembatinib was recently cleared by the China CDE to enter a registrational Phase III study in patients with SDH-deficient GIST. We will expeditiously advance this clinical development program in efforts to bring more treatment options to patients around the world."
Details of the Mini Oral presentation at this year’s ESMO (Free ESMO Whitepaper) Congress are as follows:
Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
Format: Mini oral
Presentation#: 1722MO
Category: Sarcoma
Date & Time: Friday September 13, 2024, 16:30 – 16:35 CEST
Speaker: Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center